Literature DB >> 11214128

Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study.

J Askling1, P W Dickman, P Karlén, O Broström, A Lapidus, R Löfberg, A Ekbom.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) and colorectal cancer might share a common cause and, therefore, relatives of patients with IBD could be at increased risk of this malignant disease. We aimed to assess cancer rates among first-degree relatives of patients with IBD to try to determine whether an association between the two diseases exists.
METHODS: In a population-based study, we identified 114,102 first-degree relatives by registry linkage and followed them up for cancer occurrence. We used standardised incidence ratio (SIR) of cancer as relative risk.
FINDINGS: 560 colorectal cancers were identified among relatives. First-degree relatives of patients with Crohn's disease or ulcerative colitis were not at increased risk of cancer (SIR 0.90, 95% CI 0.82-0.97). The relative risk was 0.96 (0.87-1.06, n=379) for colon cancer and 0.78 (0.68-0.91, 181) for rectal cancer. The SIRs were not affected by age, relation to patient, or type or extent of IBD in the patient. Relatives of patients with both IBD and colorectal cancer had an 80% increased risk of colorectal cancer.
INTERPRETATION: Our results do not endorse a common cause of IBD and colorectal cancer. The slightly decreased relative risk for colorectal cancer among relatives could indicate the proportion of all colorectal cancer cases attributable to IBD.

Entities:  

Mesh:

Year:  2001        PMID: 11214128     DOI: 10.1016/S0140-6736(00)03612-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

1.  Survival in elderly patients with ulcerative colitis and colorectal cancer.

Authors:  Wojciech Blonski; Gary R Lichtenstein
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

Review 2.  Radical induction theory of ulcerative colitis.

Authors:  Jay Pravda
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

Review 3.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

Review 4.  Precancer in ulcerative colitis: the role of the field effect and its clinical implications.

Authors:  Kathryn T Baker; Jesse J Salk; Teresa A Brentnall; Rosa Ana Risques
Journal:  Carcinogenesis       Date:  2018-01-12       Impact factor: 4.944

Review 5.  Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?

Authors:  Jessica K Dyson; Matthew D Rutter
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

6.  Current management of inflammatory bowel disease and colorectal cancer.

Authors:  Mark C Mattar; Denver Lough; Michael J Pishvaian; Aline Charabaty
Journal:  Gastrointest Cancer Res       Date:  2011-03

Review 7.  Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences.

Authors:  Amosy E M'Koma; Harold L Moses; Samuel E Adunyah
Journal:  Int J Colorectal Dis       Date:  2011-02-11       Impact factor: 2.571

Review 8.  Ulcerative colitis-associated colorectal cancer.

Authors:  Masakazu Yashiro
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

9.  NF-κB pathway in colitis-associated cancers.

Authors:  Emilie Viennois; Fengyuan Chen; Didier Merlin
Journal:  Transl Gastrointest Cancer       Date:  2013-01-01

Review 10.  Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.

Authors:  Millie D Long; Susan Hutfless; Michael D Kappelman; Hamed Khalili; Gilaad G Kaplan; Charles N Bernstein; Jean Frederic Colombel; Corinne Gower-Rousseau; Lisa Herrinton; Fernando Velayos; Edward V Loftus; Geoffrey C Nguyen; Ashwin N Ananthakrishnan; Amnon Sonnenberg; Andrew Chan; Robert S Sandler; Ashish Atreja; Samir A Shah; Kenneth J Rothman; Neal S Leleiko; Renee Bright; Paolo Boffetta; Kelly D Myers; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.